Research
Hormonal
GLP-1 and GIP agonists (e.g., semaglutide) significantly improve glycemic control, promote weight loss, and provide cardiovascular and renal protection in patients with obesity and type 2 diabetes.
If you have obesity and type 2 diabetes, ask your doctor about GLP-1/GIP agonists. These drugs treat the underlying biology, help you lose weight, and protect your heart and kidneys.
StrongSupportsHIGH confidence
These agents not only improve glycemic control and promote weight loss, but they also have favorable cardiovascular outcomes, renal protection, and overall mortality.
Why this rating
Cites multiple large-scale RCTs (SUSTAIN, STEP trials).
Source
Obesity as a Disease: A Primer on Clinical and Physiological Insights
Aayush Shah et al. · Methodist DeBakey Cardiovascular Journal · 2025
DOI 10.14797/mdcvj.1515
narrative_reviewCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic, progressive, relapsing, multifactorial neurobehavioral disease driven by complex brain-gut-adipose interactions, not merely a lack of willpower.Strong
- Obesity is associated with increased risk of various cancers (breast, colorectal, endometrial, etc.) through mechanisms involving chronic inflammation, insulin resistance, and hormonal changes.Strong
- The Edmonton Obesity Staging System (EOSS) provides a more comprehensive clinical management framework than BMI alone by categorizing obesity based on health complications.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →